• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

March 11, 2019
Company Drug/Device Medical Condition Status
AOBiome Therapeutics, Inc. B244 pediatric patients with atopic dermatitis (eczema) Phase Ib trial initiated enrolling 36 subjects aged 2 to 17 years
Forbius AVID200 diffuse cutaneous systemic sclerosis (SSc) Phase Ib trial initiated
I-Mab Biopharma TJ107 (HyLeukin) advanced solid tumors Phase Ib/IIa trial initiated enrolling 58 subjects in China
Odonate Therapeutics, Inc. tesetaxel locally advanced or metastatic breast cancer (LA/MBC) Phase II trial initiated enrolling 125 subjects with human epidermal growth factor receptor 2 (HER2) negative, hormone receptor (HR) positive disease who have not previously received a taxane
Eidos Therapeutics, Inc. AG10 transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) Phase III trial initiated enrolling 510 subjects with symptomatic ATTR-CM, associated with either wild-type or mutant TTR, with New York Heart Association Class I-III symptoms
Inovio VGX-3100 cervical dysplasia caused by human papillomavirus (HPV) Phase III trial initiated enrolling adult female subjects with HPV 16/18 positive biopsy-proven cervical HSIL, otherwise known as cervical intraepithelial neoplasia (CIN) 2 or 3
Acceleron Pharma, Inc. ACE-083 Charcot-Marie-Tooth disease (CMT) Orphan Drug designation granted by the FDA
Mitochon Pharmaceuticals MP-101 Huntington’s Disease Orphan Drug designation granted by the FDA
Celgene Corporation fedratinib myelofibrosis Priority Review granted by the FDA
NKMax America SNK01 refractory cancer IND approval granted by the FDA
Breckenridge Pharmaceutical, Inc. Imatinib Mesylate Tablets cancer ANDA approval granted by the FDA
Janssen Spravato major depressive disorder Approval granted by the FDA
Baxter International, Inc. eptifibatide acute coronary syndrome (ACS) Approval granted by the FDA
Adlon Therapeutics, L.P.m Adhansia XR (methylpheni-date hydrochloride) extended-release capsules CII Attention-Deficit/Hyperactivity Disorder (ADHD) Approval granted by the FDA

 

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing